JP2009543844A5 - - Google Patents

Info

Publication number

JP2009543844A5

JP2009543844A5 JP2009519957A JP2009519957A JP2009543844A5 JP 2009543844 A5 JP2009543844 A5 JP 2009543844A5 JP 2009519957 A JP2009519957 A JP 2009519957A JP 2009519957 A JP2009519957 A JP 2009519957A JP 2009543844 A5 JP2009543844 A5 JP 2009543844A5

Authority

JP

Japan

Prior art keywords

disease

use according

dabigatran

compound

pregnant women

Prior art date

2007-07-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 7
• 229960000288 dabigatran etexilate Drugs 0.000 claims 5
• KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
• -1 N-hydroxyamidino Chemical group 0.000 claims 4
• 239000002253 acid Substances 0.000 claims 4
• 201000010099 disease Diseases 0.000 claims 4
• 150000003839 salts Chemical class 0.000 claims 4
• 208000006011 Stroke Diseases 0.000 claims 3
• 229960003850 dabigatran Drugs 0.000 claims 3
• YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 3
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
• 206010019280 Heart failures Diseases 0.000 claims 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
• 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
• 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
• 210000004556 brain Anatomy 0.000 claims 2
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 2
• CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
• 208000019838 Blood disease Diseases 0.000 claims 1
• 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
• 206010010356 Congenital anomaly Diseases 0.000 claims 1
• 208000005189 Embolism Diseases 0.000 claims 1
• 108090000790 Enzymes Proteins 0.000 claims 1
• 102000004190 Enzymes Human genes 0.000 claims 1
• 206010018910 Haemolysis Diseases 0.000 claims 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
• 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims 1
• 102000007625 Hirudins Human genes 0.000 claims 1
• 108010007267 Hirudins Proteins 0.000 claims 1
• 206010061216 Infarction Diseases 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 208000025747 Rheumatic disease Diseases 0.000 claims 1
• 206010059054 Shunt thrombosis Diseases 0.000 claims 1
• 108090000190 Thrombin Proteins 0.000 claims 1
• 208000007536 Thrombosis Diseases 0.000 claims 1
• 206010062546 Thrombosis in device Diseases 0.000 claims 1
• 208000009205 Tinnitus Diseases 0.000 claims 1
• 206010047249 Venous thrombosis Diseases 0.000 claims 1
• 229960003856 argatroban Drugs 0.000 claims 1
• KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims 1
• 206010003119 arrhythmia Diseases 0.000 claims 1
• 230000006793 arrhythmia Effects 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 238000002512 chemotherapy Methods 0.000 claims 1
• 208000028831 congenital heart disease Diseases 0.000 claims 1
• 210000004351 coronary vessel Anatomy 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 238000000502 dialysis Methods 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 230000002526 effect on cardiovascular system Effects 0.000 claims 1
• 206010014599 encephalitis Diseases 0.000 claims 1
• 229940088598 enzyme Drugs 0.000 claims 1
• 210000003709 heart valve Anatomy 0.000 claims 1
• 208000014951 hematologic disease Diseases 0.000 claims 1
• 208000018706 hematopoietic system disease Diseases 0.000 claims 1
• 230000008588 hemolysis Effects 0.000 claims 1
• 229940006607 hirudin Drugs 0.000 claims 1
• WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims 1
• 150000004677 hydrates Chemical class 0.000 claims 1
• 230000007574 infarction Effects 0.000 claims 1
• 229950003291 inogatran Drugs 0.000 claims 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
• 208000017169 kidney disease Diseases 0.000 claims 1
• 210000004185 liver Anatomy 0.000 claims 1
• 210000004072 lung Anatomy 0.000 claims 1
• 230000008774 maternal effect Effects 0.000 claims 1
• 230000001404 mediated effect Effects 0.000 claims 1
• DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims 1
• 229960002137 melagatran Drugs 0.000 claims 1
• 229940098779 methanesulfonic acid Drugs 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• 230000004770 neurodegeneration Effects 0.000 claims 1
• 208000015122 neurodegenerative disease Diseases 0.000 claims 1
• 230000036542 oxidative stress Effects 0.000 claims 1
• 229940002612 prodrug Drugs 0.000 claims 1
• 239000000651 prodrug Substances 0.000 claims 1
• 239000012453 solvate Substances 0.000 claims 1
• 208000011580 syndromic disease Diseases 0.000 claims 1
• 229960004072 thrombin Drugs 0.000 claims 1
• 201000005665 thrombophilia Diseases 0.000 claims 1
• 231100000886 tinnitus Toxicity 0.000 claims 1
• 229960001522 ximelagatran Drugs 0.000 claims 1
• ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims 1